Cat. No. 1675
Chemical Name: 5,6-Dihydro-2,3-dimethoxy-6,6-dimet
Biological ActivityNovel, selective inhibitor of interleukin-5 (IL-5) (IC50 = 0.45 - 1 mM). Inhibits IL-5-prolonged eosinophil survival and IL-5-induced tyrosine phosphorylation of JAK2 without inhibiting GM-CSF-mediated effects. Inhibits antigen-induced eosinophil and lymphocyte recruitment in rat airways in vivo, without affecting peripheral blood or bone marrow leukocytes.
Licensing InformationSold with the permission of Astellas Pharma Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Morokata et al (2005) Effect of a novel interleukin-5 receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into the airway of BDF1 mice. Immunol.Lett. 98 161. PMID: 15790522.
Morokata et al (2004) Effect of a novel interleukin-5 receptor antagonist, YM-90709 (2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline), on antigen-induced airway inflammation in BN rats. Int.Immunopharmacol. 4 873. PMID: 15182727.
Morokata et al (2002) Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int.Immunopharmacol. 2 1693. PMID: 12469943.
If you know of a relevant reference for YM 90709 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses YM 90709 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: YM 90709, supplier, Interleukin-5, receptor, inhibitors, inhibits, antagonists, IL, receptors, interleukins, cytokines, YM90709, IL-5, inhibitor, Tocris Bioscience, Cytokine Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Dual α9β/1α4β1 integrin inhibitor; preferentially mobilizes HSCsATN 161
α5β1 integrin receptor antagonistFSL 1
TLR2/6 agonist (also a putative TLR10 ligand)
June 14 - 17, 2017
Boston, MA, USA